

## **FOREIGN INVESTMENT REVIEW BOARD APPROVAL RECEIVED FOR BROOKFIELD TRANSACTION AND ASSOCIATED PROPERTY TRANSACTIONS**

**19 MARCH 2019**

Healthscope Limited ("Healthscope") today announced that Brookfield Business Partners ("Brookfield"), NorthWest Healthcare and Medical Properties Trust ("MPT") have received written correspondence from the Foreign Investment Review Board ("FIRB") that the Australian Government has no objections under the Foreign Acquisitions and Takeovers Act 1975 (Cth) to:

- the proposed acquisition by Brookfield of 100% of Healthscope by way of scheme of arrangement and a simultaneous off-market takeover offer (announced on 1 February 2019); and
- the associated sale and leaseback of 22 freehold properties by Healthscope to NorthWest and MPT.

Brookfield has confirmed that the correspondence satisfies the relevant conditions contained in the Implementation Deed between Healthscope and Brookfield.

Healthscope remains committed to sending an Explanatory Booklet to Healthscope shareholders in April / May 2019, following which a Scheme meeting is expected to be held in May / June 2019.

### **Further enquiries:**

#### Investors

David Shirer  
General Manager Investor Relations  
Phone: +61 3 9926 7766 / +61 407 512 521

Natalie Rachele  
Manager Investor Relations  
Phone: +61 3 9926 7522 / +61 413 685 164

#### Media

Jared Lynch  
Senior Manager Corporate Affairs  
Phone: +61 428 359 065

Lisa Keenan  
Nightingale Communications  
Phone: +61 409 150 771

### **About Healthscope**

Healthscope (ticker: HSO) is a leading private healthcare provider with 43 private hospitals in Australia and pathology operations across New Zealand.

Healthscope has a team of 18,000 people and 17,500 Accredited Medical Practitioners, providing care to patients ranging from pathology tests to complex surgery.

We place the highest priority on quality clinical outcomes, transparency of reporting and elevating the overall patient experience. Healthscope was the first private hospital operator in Australia to report performance against quality and clinical outcome metrics publicly, just one part of our program to maintain and continually improve our high standards.